We updated the design of this site on December 18, 2017. Learn more.
ClinicalTrials.gov Menu

Study of Standard CHOP Versus Biweekly CHOP in Aggressive Non-Hodgkin's Lymphoma (JCOG9809)

The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our disclaimer for details.
ClinicalTrials.gov Identifier: NCT00133302
Recruitment Status : Terminated
First Posted : August 23, 2005
Last Update Posted : January 18, 2007
Ministry of Health, Labour and Welfare, Japan
Information provided by:
Japan Clinical Oncology Group

Brief Summary:
The purpose of this trial is to investigate the clinical benefit of the dose intensified regimen, Bi-CHOP in comparison to standard CHOP for advanced intermediate or high grade non-Hodgkin's lymphoma (NHL).

Condition or disease Intervention/treatment Phase
Non-Hodgkin's Lymphoma Drug: Standard CHOP Drug: Bi-CHOP (dose intensified CHOP) Phase 3

Detailed Description:
The purpose of JCOG9809 was to determine whether treatment results of aggressive NHL could be improved by shortening intervals of CHOP chemotherapy with the prophylactic use of G-CSF. The primary endpoint was Progression Free Survival (PFS), and the planned accrual was 450. Until December, 2002, 323 patients with advanced aggressive NHL were randomized to standard CHOP arm (CHOP x 8, every three weeks) and biweekly CHOP arm (CHOP x 8, every two weeks).

Study Type : Interventional  (Clinical Trial)
Estimated Enrollment : 450 participants
Allocation: Randomized
Intervention Model: Parallel Assignment
Masking: None (Open Label)
Primary Purpose: Treatment
Official Title: Randomized Phase III Study of Standard CHOP (S-CHOP) Versus Biweekly CHOP (Bi-CHOP) in Aggressive Non-Hodgkin's Lymphoma (JCOG9809)
Study Start Date : February 1999
Estimated Study Completion Date : February 2005

Resource links provided by the National Library of Medicine

MedlinePlus related topics: Lymphoma
U.S. FDA Resources

Primary Outcome Measures :
  1. Progression free survival

Secondary Outcome Measures :
  1. Overall survival
  2. Complete remission rate
  3. Toxicity

Information from the National Library of Medicine

Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the contacts provided below. For general information, Learn About Clinical Studies.

Ages Eligible for Study:   15 Years to 69 Years   (Child, Adult, Senior)
Sexes Eligible for Study:   All
Accepts Healthy Volunteers:   No

Inclusion Criteria:

  • Intermediate- or high-grade non-Hodgkin's lymphoma, excluding cutaneous t-cell lymphoma (CTCL), adult T-cell leukemia-lymphoma (ATL) and T-cell lymphoblastic lymphoma (T-LbL) (Working Formulation)
  • Ann Arbor stage: II, III, IV
  • No prior chemotherapy or radiotherapy
  • Age: 15 to 69
  • Performance status (PS): 0, 1, 2
  • WBC >= 3,000 /mm3, ANC >= 1,200 /mm3, Platelet >= 75,000 /mm3
  • GOT/GPT <= 5 x Normal Upper Limit, T-Bil <= 2.0 mg/dL
  • Creatinine <= 2.0 mg/dL
  • Normal ECG, Ejection Fraction >= 50%
  • PaO2 >= 65 mmHg
  • Written informed consent

Exclusion Criteria:

  • Uncontrollable diabetes mellitus
  • Severe complication (infection, heart failure, renal failure, liver failure, etc)
  • Anamnesis of heart disease
  • Acute or chronic hepatitis, liver cirrhosis and portal hypertension
  • Synchronous or metachronous malignancy
  • Severe pulmonary dysfunction
  • Central nervous system (CNS) invasion
  • HIV positive
  • Hepatitis B surface antigen (HBs-Ag) positive
  • Hepatitis C virus antibody (HCV-Ab) positive

Information from the National Library of Medicine

To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.

Please refer to this study by its ClinicalTrials.gov identifier (NCT number): NCT00133302

Tokai University
Isehara, Kanagawa, Japan, 259-1193
Sponsors and Collaborators
Japan Clinical Oncology Group
Ministry of Health, Labour and Welfare, Japan
Study Chair: Tomomitsu Hotta, MD, PhD Tokai University

Additional Information:
Publications automatically indexed to this study by ClinicalTrials.gov Identifier (NCT Number):
ClinicalTrials.gov Identifier: NCT00133302     History of Changes
Other Study ID Numbers: JCOG9809
First Posted: August 23, 2005    Key Record Dates
Last Update Posted: January 18, 2007
Last Verified: August 2006

Keywords provided by Japan Clinical Oncology Group:
Non-Hodgkin's lymphoma
intermediate-grade lymphoma
high-grade lymphoma
CHOP protocol
granulocyte-colony stimulating factor

Additional relevant MeSH terms:
Lymphoma, Non-Hodgkin
Neoplasms by Histologic Type
Lymphoproliferative Disorders
Lymphatic Diseases
Immunoproliferative Disorders
Immune System Diseases